Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.1849
+0.0069 (3.88%)
At close: Apr 1, 2025, 4:00 PM
0.1780
-0.0069 (-3.73%)
After-hours: Apr 1, 2025, 4:37 PM EDT
Ernexa Therapeutics Employees
Ernexa Therapeutics had 6 employees as of December 31, 2024. The number of employees decreased by 2 or -25.00% compared to the previous year.
Employees
6
Change (1Y)
-2
Growth (1Y)
-25.00%
Revenue / Employee
$97,000
Profits / Employee
-$7,425,833
Market Cap
9.66M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6 | -2 | -25.00% |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Dec 31, 2022 | 9 | -1 | -10.00% |
| Dec 31, 2021 | 10 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ERNA News
- 4 weeks ago - Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline - GlobeNewsWire
- 2 months ago - Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer - GlobeNewsWire
- 2 months ago - Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors - GlobeNewsWire
- 4 months ago - Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing - GlobeNewsWire
- 5 months ago - Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success - GlobeNewsWire
- 5 months ago - Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases - GlobeNewsWire
- 11 months ago - Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs - GlobeNewsWire
- 11 months ago - Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board - GlobeNewsWire